Elysium Health study links Basis to fewer menopause symptoms
A seven-day Basis pilot linked 250 mg nicotinamide riboside and 50 mg pterostilbene to fewer hot flashes, bloating and poor sleep in 32 symptomatic women.
Elysium Health’s Basis supplement reduced disruptive menopause-transition symptoms and raised the E2/E1 ratio in a new pilot study. The company’s flagship NAD+ formula was tested in an open-label trial, not a blinded placebo-controlled study.
The paper, published May 13 in Frontiers in Aging, enrolled 40 healthy women over age 35 under ClinicalTrials.gov identifier NCT04841499. Thirty-two participants self-reported symptoms associated with the menopause transition, while eight reported no or minimal symptoms. All took the recommended daily dose of Basis for seven days: 250 mg nicotinamide riboside and 50 mg pterostilbene.
In the symptomatic group, women self-reported 50% or greater reductions in the frequency and severity of hot flashes, bloating and poor sleep. The non-symptomatic group showed no significant changes. The study also found a significant increase in the E2/E1 ratio, a marker of the balance between estradiol and estrone. Urine was collected at baseline and after the intervention to measure E1, E2 and vitamin B3 catabolome changes.
The trial aimed to determine whether seven days of Basis supplementation increased natural estradiol production measured in urinary waste. Its rationale leaned on the idea that NAD+ and estradiol both decline with age, and that lower estradiol is associated with menopause-transition symptoms.
Elysium says Basis has been backed by more than 20 human clinical trials, including a 2017 double-blind, randomized, placebo-controlled study that found Basis increased NAD+ by an average of 40% from baseline.
The menopause study was complete and expected to publish in 2025. Yousin Suh, Ph.D., Columbia University’s Charles and Marie Robertson Professor of Reproductive Sciences in Obstetrics and Gynecology, Professor of Genetics and Development, and director of the Reproductive Aging Program, joined its Scientific Advisory Board. Suh said women’s health, reproductive aging and longevity are deeply interconnected yet remain underrepresented in aging research.
This article was produced by Prism’s automated news system from verified source data, official records, and press releases, then run through automated quality and moderation checks before publishing. The system is built and supervised by the people who set the standards it runs under. Read our full AI policy.
Did this article answer your question?
